Patents by Inventor Nir Hacohen

Nir Hacohen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220397568
    Abstract: The present invention provides isolated immune cells, immune cell populations and compositions, as well as markers, marker signatures and molecular targets characterising the immune cells. The cell products, substances, compositions, markers, marker signatures, molecular targets, kits of parts and methods of the present invention provide for new ways to characterise, evaluate and modulate the immune system and immune responses.
    Type: Application
    Filed: August 17, 2017
    Publication date: December 15, 2022
    Inventors: Alexandra-ChloƩ VILLANI, Rahul SATIJA, Aviv Regev, Nir HACOHEN
  • Patent number: 11452768
    Abstract: The present invention relates to neoplasia vaccine or immunogenic composition administered in combination with other agents, such as checkpoint blockade inhibitors for the treatment or prevention of neoplasia in a subject.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: September 27, 2022
    Assignees: The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc., The General Hospital Corporation
    Inventors: Nir Hacohen, Catherine J. Wu, Edward F. Fritsch
  • Publication number: 20220299511
    Abstract: Provided herein, in some embodiments, are methods for analyzing immune cells in a blood sample from a subject having, suspected of having, or being at risk for bacterial sepsis. The present disclosure is based, at least in part, on the finding that certain immune cells are expanded in subjects having sepsis compared to healthy subjects.
    Type: Application
    Filed: June 17, 2020
    Publication date: September 22, 2022
    Applicants: The Broad Institute, Inc., Massachusetts Institute of Technology, The General Hospital Corporation
    Inventors: Miguel Reyes, Nir Hacohen, Paul C. Blainey, Michael R. Filbin, Marcia B. Goldberg, Roby P. Bhattacharyya
  • Publication number: 20220282333
    Abstract: The present invention provides methods of predicting a patient's response to immunotherapy, in particular checkpoint blockade therapy, and provides for treatments. Disclosed herein are novel combinations of factors identified in tumors used to predict response and provide for treatments. Also, disclosed are methods of treatment that can shift a tumor to a responder phenotype.
    Type: Application
    Filed: August 13, 2020
    Publication date: September 8, 2022
    Inventors: Samuel Freeman, Moshe Sade-Feldman, Nir Hacohen, Gad Getz, Matthew Meyerson
  • Publication number: 20220088180
    Abstract: Immunogenic compositions comprising one or more polypeptides, wherein the one or more polypeptides: is capable of binding to Major Histocompatibility Complex (MHC) class I, and is derived from one or more proteins of SARS-CoV-2. Also provided include methods of treating and preventing diseases using the immunogenic compositions.
    Type: Application
    Filed: August 31, 2021
    Publication date: March 24, 2022
    Inventors: Pardis SABETI, Shira Weingarten-Gabbay, Susan Klaeger, Jenn Abelin, Mohsan Saeed, Nir Hacohen, Siranush Sarkizova, Steven Carr, Karl Clauser
  • Publication number: 20220034869
    Abstract: A system and method for isolating target substrates includes a microfluidic chip, comprising a plurality of processing units, each processing unit comprising: an inlet port, a plurality of first chambers connected to the inlet port by a fluid channel, the fluid channel comprising a plurality of valves, a plurality of second chambers, each of the second chambers connected to a respective first chamber by a fluid channel, each fluid channel including a controllable blocking valve, and a plurality of respective outlet ports, each outlet port in fluid communication with a respective one of said second chambers and each outlet port including a blocking valve. A magnet is adjacent the microfluidic chip and is movable relative to the microfluidic chip. A valve control is capable of actuating certain ones of the controllable blocking valves in response to a control signal.
    Type: Application
    Filed: January 29, 2021
    Publication date: February 3, 2022
    Applicants: THE BROAD INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGY, THE GENERAL HOSPITAL CORPORATION
    Inventors: Paul Blainey, Dwayne Vickers, Nir Hacohen
  • Publication number: 20220031725
    Abstract: Provided herein, in some embodiments, are methods for treating age-associated conditions, including systemic inflammation and disease, via enhanced DNA degradation.
    Type: Application
    Filed: September 25, 2019
    Publication date: February 3, 2022
    Applicant: The General Hospital Corporation
    Inventors: Yuk Yuen Lan, Nir Hacohen
  • Publication number: 20220002400
    Abstract: Methods of treating influenza A are provided, comprising administering to a subject at least one agent selected from a WDR7 inhibitor, a CCDC115 inhibitor, a TMEM199 inhibitor, and a CMTR1 inhibitor.
    Type: Application
    Filed: September 24, 2021
    Publication date: January 6, 2022
    Inventors: Bo Li, Nir Hacohen, J. Kenneth Baillie
  • Patent number: 11197467
    Abstract: The invention involves a method for modulating leukocyte activity, comprising delivering to a leukocyte a vector containing nucleic acid molecule(s), whereby the leukocyte contains Cas9 and the vector expresses one or more RNAs to guide the Cas9 to introduce mutations in one or more target genetic loci in the leukocyte, thereby modulating expression of one or more genes expressed in the leukocyte. The invention also involves identifying genes associated with leukocyte responses and experimental modeling of aberrant leukocyte activation and diseases associated with leukocytes by introducing mutations into leukocytes. The invention comprehends testing putative treatments with such models, e.g., testing putative chemical compounds that may be pharmaceutically relevant for treatment or gene therapy that may be relevant for treatment, or combinations thereof. The invention allows for the study of genetic diseases and putative treatments to better understand and alleviate leukocyte associated diseases.
    Type: Grant
    Filed: March 24, 2017
    Date of Patent: December 14, 2021
    Assignees: The Broad Institute, Inc., Massachusetts Institute of Technology, The General Hospital Corporation
    Inventors: Aviv Regev, Oren Parnas, Marko Jovanovic, Nir Hacohen, Thomas Eisenhaure
  • Publication number: 20210382068
    Abstract: Adaptive immune responses rely on the ability of cytotoxic T cells to identify and eliminate cells displaying disease-specific antigens on human leukocyte antigen (HLA) class I molecules. Investigations into antigen processing and display have immense implications in human health, disease and therapy. To extend understanding of the rules governing antigen processing and presentation, immunopurified peptides from B cells, each expressing a single HLA class I allele, were profiled. A resource dataset containing thousands of peptides bound to distinct class I HLA-A, -B, and -C alleles was generated by implementing a novel allele-specific database search strategy. Applicants discovered new binding motifs, established the role of gene expression in peptide presentation and improved prediction of HLA-peptide binding by using these data to train machine-learning models. These streamlined experimental and analytic workflows enable direct identification and analysis of endogenously processed and presented antigens.
    Type: Application
    Filed: October 2, 2019
    Publication date: December 9, 2021
    Inventors: Derin Keskin, Siranush Sarkizova, Susan Klaeger, Karl Clauser, Steven Carr, Nir Hacohen, Catherine J. Wu
  • Publication number: 20210379168
    Abstract: The present disclosure relates to methods for profiling subject specific and personalized T cell receptor (TCR) repertoires using a single-cell sequencing method. More particularly, disclosed are methods for determining binding of T cell receptors to subject specific neoantigens. In addition, the techniques herein may identify the antigenic targets of T cell receptors in the context of tumor neoantigens. Moreover, the present disclosure enables the discovery of T cell targets in numerous diseases, with implications for understanding the basic mechanisms of the mammalian immune response and for developing antigen-specific diagnostic markers and therapies. Finally, cloned TCRs can be used to formulate personalized immunotherapies for those inflicted with a disease, such as cancer.
    Type: Application
    Filed: March 30, 2021
    Publication date: December 9, 2021
    Inventors: Nir Hacohen, Catherine Ju-Ying Wu, Edward F. Fritsch, Ute E. Burkhardt
  • Publication number: 20210262039
    Abstract: In one aspect, provided herein is a method comprising: (a) (i) determining cytolytic activity in a tumor from the subject; and/or (ii) determining genetic alterations associated with cytolytic activity in the tumor; and (b) administering an immunotherapeutic agent to the subject if (i) cytolytic activity is detected in the tumor and/or (ii) a genetic alteration associated with induction of cytolytic activity, tumor resistance to cytolytic activity and/or suppression of cytolytic activity is detected in the tumor.
    Type: Application
    Filed: February 19, 2021
    Publication date: August 26, 2021
    Inventors: Nir Hacohen, Michael S. Rooney
  • Publication number: 20210220455
    Abstract: The invention provides a method of making a personalized neoplasia vaccine for a subject diagnosed as having a neoplasia, which includes identifying a plurality of mutations in the neoplasia, analyzing the plurality of mutations to identify a subset of at least five neo-antigenic mutations predicted to encode neo-antigenic peptides, the neo-antigenic mutations selected from the group consisting of missense mutations, neoORF mutations, and any combination thereof, and producing, based on the identified subset, a personalized neoplasia vaccine.
    Type: Application
    Filed: November 4, 2020
    Publication date: July 22, 2021
    Inventors: Nir Hacohen, Catherine Ju-Ying Wu, Edward F. Fritsch
  • Publication number: 20210139914
    Abstract: The present disclosure provides, in part, methods of discovering immunotherapy targets in vivo, therapeutic compositions (e.g., shRNA, immunoresponsive cells expressing shRNA and/or a chimeric antigen receptors (CAR)), and methods of use thereof.
    Type: Application
    Filed: November 24, 2020
    Publication date: May 13, 2021
    Applicants: Dana-Farber Cancer Institute, Inc., The General Hospital Corporation d/b/a Massachusetts General Hospital
    Inventors: Kai W. Wucherpfennig, Glenn Dranoff, Penghui Zhou, Donald Shaffer, Nir Hacohen, Harvey I. Cantor, Diana Alvarez Arias
  • Patent number: 10993997
    Abstract: The present disclosure relates to methods for profiling subject specific and personalized T cell receptor (TCR) repertoires using a single-cell sequencing method. More particularly, disclosed are methods for determining binding of T cell receptors to subject specific neoantigens. In addition, the techniques herein may identify the antigenic targets of T cell receptors in the context of tumor neoantigens. Moreover, the present disclosure enables the discovery of T cell targets in numerous diseases, with implications for understanding the basic mechanisms of the mammalian immune response and for developing antigen-specific diagnostic markers and therapies. Finally, cloned TCRs can be used to formulate personalized immunotherapies for those inflicted with a disease, such as cancer.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: May 4, 2021
    Assignees: The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc., The General Hospital Corporation
    Inventors: Nir Hacohen, Catherine Ju-Ying Wu, Edward F. Fritsch, Ute E. Burkhardt
  • Patent number: 10975442
    Abstract: In one aspect, provided herein is a method comprising: (a) (i) determining cytolytic activity in a tumor from the subject; and/or (ii) determining genetic alterations associated with cytolytic activity in the tumor; and (b) administering an immunotherapeutic agent to the subject if (i) cytolytic activity is detected in the tumor and/or (ii) a genetic alteration associated with induction of cytolytic activity, tumor resistance to cytolytic activity and/or suppression of cytolytic activity is detected in the tumor.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: April 13, 2021
    Assignees: Massachusetts Institute of Technology, The General Hospital Corporation
    Inventors: Nir Hacohen, Michael S. Rooney
  • Publication number: 20210104294
    Abstract: The present invention discloses a method for predicting peptides that are capable of binding to HLA molecules that incorporate the crystal structure of HLA molecules. An improved HLA-specific peptide docking workflow is used to simulate the occupancy of a peptide on the binding pocket of an HLA molecule, and three models are trained to predict the binding of the peptide to HLA molecules. The results show that these models predict HLA-allele specific binding peptides with extremely high accuracy.
    Type: Application
    Filed: October 2, 2020
    Publication date: April 8, 2021
    Inventors: Nir Hacohen, Catherine J. Wu, Siranush Sarkizova, Matthew Bakalar
  • Patent number: 10962527
    Abstract: A system and method for isolating target substrates includes a microfluidic chip, comprising a plurality of processing units, each processing unit comprising: an inlet port, a plurality of first chambers connected to the inlet port by a fluid channel, the fluid channel comprising a plurality of valves, a plurality of second chambers, each of the second chambers connected to a respective first chamber by a fluid channel, each fluid channel including a controllable blocking valve, and a plurality of respective outlet ports, each outlet port in fluid communication with a respective one of said second chambers and each outlet port including a blocking valve. A magnet is adjacent the microfluidic chip and is movable relative to the microfluidic chip. A valve control is capable of actuating certain ones of the controllable blocking valves in response to a control signal.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: March 30, 2021
    Assignees: THE BROAD INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGY, THE GENERAL HOSPITALL CORPORATION
    Inventors: Paul Blainey, Dwayne Vickers, Nir Hacohen
  • Publication number: 20210047694
    Abstract: The present invention is generally directed to a colorectal (CRC) cell atlas that provides methods of predicting outcomes of cancer patients and therapeutic targets for treating patients in need thereof. The atlas may be used to predict a response to immunotherapy, in particular checkpoint blockade therapy and adoptive cell transfer. Disclosed herein are previously unidentified gene programs in tumors that can be used to predict response and provide for therapeutic targets that can be used to shift a tumor to a responsive phenotype.
    Type: Application
    Filed: August 17, 2020
    Publication date: February 18, 2021
    Inventors: Aviv Regev, Nir Hacohen, Vijay K. Kuchroo, Ana Carrizosa Anderson, Orit Rozenblatt-Rosen, Jonathan Chen, Karin Pelka, Matan Hofree
  • Patent number: 10876120
    Abstract: The present disclosure provides, in part, methods of discovering immunotherapy targets in vivo, therapeutic compositions (e.g., shRNA, immunoresponsive cells expressing shRNA and/or a chimeric antigen receptors (CAR)), and methods of use thereof.
    Type: Grant
    Filed: April 3, 2018
    Date of Patent: December 29, 2020
    Assignees: DANA-FARBER CANCER INSTITUTE, INC, THE GENERAL HOSPITAL CORPORATION
    Inventors: Kai W. Wucherpfennig, Glenn Dranoff, Penghui Zhou, Donald Shaffer, Nir Hacohen, Harvey I. Cantor, Diana Alvarez Arias